-
Fecal Microbiota Transplantation Shows Promise for First-Line Primary C Diff Treatment
18 Jun 2025 18:53 GMT
… published in Annals of Internal Medicine.2
A 2024 American Gastroenterological … studies.3 While antibiotic treatment with vancomycin or fidaxomicin is currently recommended for … noninferiority, phase 3 randomized clinical trial of adult patients with primary …
-
Fecal Microbiota Transplant Found Noninferior to Antibiotic as Initial Treatment for C. Diff
18 Jun 2025 00:13 GMT
… the Annals of Internal Medicine.
Frederik Emil Juul, … therapy with antibiotics like vancomycin or fidaxomicin for primary … , open-label noninferiority trial across 20 hospitals and … treated participants required additional treatment compared to 4 vancomycin …
-
Acurx Pharmaceuticals Shares Are Up Today: What's Going On?
17 Jun 2025 18:59 GMT
… of Acurx Pharmaceuticals inc. ACXP … clinical trial for ibezapolstat, a novel antibiotic targeting C … trials and continue advancing its antibiotic candidate as a front-line treatment … treatments such as vancomycin and fidaxomicin. Acurx emphasized the drug …
-
Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI
17 Jun 2025 11:51 GMT
… antibiotics for treatment of CDI: oral vancomycin (VAN) or fidaxomicin … other patients. The medical community should be … 3 trials, in accordance with the applicable FDA Guidance … trial-data-for-ibezapolstat-in-cdi-302483504.html
SOURCE Acurx Pharmaceuticals …
-
Acurx Pharmaceuticals Soars as Breakthrough Antibiotic Data Hits the Headlines
17 Jun 2025 23:37 GMT
… up, traders, because Acurx Pharmaceuticals (NASDAQ: ACXP) is … a new kind of antibiotic targeting Clostridioides difficile infections … 3 trials, the final hurdle before seeking FDA approval. … from vancomycin and fidaxomicin—cheap, established drugs—won’t vanish …
-
Heightened Awareness, Effective Treatment Options Critical to C difficile Management
17 Jun 2025 15:36 GMT
… care center for treatment due to an infection receive antibiotics. Unfortunately, many … use of the specific medicine. Historically, the treatment of mild-to-moderate … such as vancomycin (Firvanq; Azurity Pharmaceuticals) or fidaxomicin (Dificid; Merck & Co …
-
MAD-ID 2025 Highlights Fidaxomicin’s Role in Reducing C difficile Recurrence
10 Jun 2025 17:33 GMT
… away from traditional FMT toward FDA-approved microbiome therapies like Vowst … beyond the end of systemic antibiotic treatment, known as a vancomycin tail … also lower with fidaxomicin. Although both drugs are effective, fidaxomicin’s narrower spectrum …
-
Fidaxomicin Tied to Lower C difficile Recurrence in Immunocompromised Patients
09 Jun 2025 14:58 GMT
… stay, and outpatient medication cost.
At 28 days post-treatment, recurrence occurred … in just 5% of patients in the fidaxomicin … , “Clinically, both drugs are effective against C. difficile, but fidaxomicin has narrower …
-
Fidaxomicin Reduces Recurrence Risk in High-Risk C difficile Infections
06 Jun 2025 13:46 GMT
… severe initial infection. “These trials don’t necessarily only focus … prior hospitalization and treatment group. Even after adjustment, fidaxomicin was associated … Assessment of vancomycin versus fidaxomicin for treatment of first occurrence Clostridioides …
-
Fidaxomicin Use Remains Flat Despite Guideline Change for C difficile Treatment
30 May 2025 23:20 GMT
… the Medical University of South Carolina (MUSC), examined fidaxomicin prescribing … .918) and recurrence or treatment failure (16% vs 8%, … specialist services “recommending fidaxomicin more now that the … think of fidaxomicin as this really expensive drug that’ …